Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).

The primary results report of NCT01794143.

What the trial testedas reported · 5,047 people · 2024

Not counted

−30%−46% to −9%

Bigger than 7 in 10 for cardiovascular events

As reported

HR 0.70, 95% CI 0.54–0.91

the abstract, start to end

… risk of MACE-5 (adjusted hazard ratio, 0.70 [95% CI, 0.54-0.91]; …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

HR 0.700.54–0.91

GLP-1 receptor agonistsOther glucose-loweringCardiovascular events

1 / 3

2024

2025

2026

this paperpooled ittrialcites it